News

Chiesi USA Announces Publication of Cost-Consequence Analysis of KENGREAL® (cangrelor) in Cardiac Patients at High Risk of Complications Following PCI in the American Journal of Cardiovascular Drugs

CARY, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused...

Mindset Pharma Announces Preclinical Results Demonstrating Superior Efficacy, Safety and Shorter Duration of Action Across Multiple Next Generation Psychedelic Drug Families

Mindset has identified several potential leads across its psilocybin/psilocin and DMT/5-MeO-DMT analogs that demonstrate superior efficacy, safety and shorter duration...

error: Content is protected !!